The Experts below are selected from a list of 64152 Experts worldwide ranked by ideXlab platform
Hitoshi Ishii - One of the best experts on this subject based on the ideXlab platform.
-
Ethnic Difference in patients with type 2 diabetes mellitus in inter east asian populations a systematic review and meta analysis focusing on gene polymorphism
Journal of Diabetes, 2009Co-Authors: Masakazu Takeuchi, Kousuke Okamoto, Tatsuya Takagi, Hitoshi IshiiAbstract:Background: We previously reported that the fasting serum insulin level was significantly lower in Japanese patients than in Korean and Chinese patients, and showed evidence that a Difference in the dietary component would be one of the most influential factors for the Ethnic Difference. However, it is well known that type 2 diabetes mellitus (T2DM) results from the interaction between genetic predispositions and environmental risk factors. Therefore, we investigated Ethnic Differences by focusing on gene polymorphism, possibly related to T2DM in Japanese, Korean, and Chinese subjects. Methods: Data sources included MEDLINE and EMBASE between January 2001 and October 2008. We conducted a search for articles containing minor allele frequency (MAF) in the gene polymorphisms of peroxisome proliferator-activated receptor-γ (PPARG), inward-rectifying potassium channel Kir6.2 (KCNJ11), Calpain 10 (CAPN10), and transcription factor 7-like 2 (TCF7L2). The pooled odds ratio was calculated by using a fixed-effects model with the Mantel–Haenszel method after confirming statistical evidence of homogeneity across the Ethnicities using the Breslow–Day test. Results: The Breslow–Day test revealed that there were no statistically significant Differences between Ethnicities in pooled odds ratios for the gene polymorphisms in PPARG (P = 0.828), KCNJ11 (P = 0.194), CAPN10 (P = 0.090), and TCF7L2 (P = 0.376). Also, pooled odds ratios of each gene polymorphism in East Asians were 0.645 for PPARG (P = 0.000), 1.168 for KCNJ11 (P = 0.000), 0.967 for CAPN10 (P = 0.759), and 1.386 for TCF7L2 (P = 0.000). Conclusion: The results of this study and our previous studies suggest that behavioral and environmental risk factors have a more significant impact on Ethnic Difference in East Asian patients with T2DM compared with genetic predispositions.
-
Ethnic Difference in inter east asian subjects with normal glucose tolerance and impaired glucose regulation a systematic review and meta analysis focusing on fasting serum insulin
Diabetes Research and Clinical Practice, 2008Co-Authors: Masakazu Takeuchi, Kousuke Okamoto, Tatsuya Takagi, Hitoshi IshiiAbstract:Abstract Aims To investigate Ethnic Difference by focusing on fasting serum insulin (FSI) in inter-East Asian subjects with normal glucose tolerance (NGT) and impaired glucose regulation (IGR). Methods Data sources included MEDLINE and EMBASE between 2001 and 2007. We conducted a search for articles containing mean or geometric mean values of FSI in East Asian subjects with NGT, IGR, or type 2 diabetes (T2DM). The Monte Carlo method was used for simulation of the mean and standard deviation of individual measures in each Ethnic group; calculation of the median ratio and 95% confidence interval of individual measures between Ethnic groups. Results Twenty-two articles fully met our pre-determined criteria and were included in the meta-analysis. Results of the meta-analysis revealed that FSI level is significantly lower in Japanese subjects with NGT, IGR, or T2DM than in Korean and Chinese subjects. Conclusions Ethnic Difference in FSI level between East Asians was observed in not only T2DM patients but also subjects with NGT or IGR. The lower FSI level in Japanese subjects was accompanied by lower triglyceride level. These results suggest that Ethnic Difference in dietary habit was one of the most influential factors for the Ethnic Difference in FSI.
-
Ethnic Difference in patients with type 2 diabetes mellitus in inter east asian populations a systematic review and meta analysis focusing on fasting serum insulin
Diabetes Research and Clinical Practice, 2008Co-Authors: Masakazu Takeuchi, Kousuke Okamoto, Tatsuya Takagi, Hitoshi IshiiAbstract:Abstract Aims To investigate Ethnic Difference by focusing on fasting serum insulin (FSI) in inter-East Asian patients with type 2 diabetes. Methods Data sources included MEDLINE and EMBASE between 2001 and 2006. We conducted a search for articles containing mean or geometric mean values of FSI in East Asian patients with type 2 diabetes. The Monte Carlo method was used for simulation of the mean and standard deviation of individual measures in each Ethnic group; calculation of the median ratio and 95% confidence interval of individual measures between Ethnic groups. Results The initial search identified a total of 996 journal articles. After reviewing the titles and abstracts of these articles, 201 studies were selected for further screening and the complete papers on these studies were then reviewed in detail. Of these, seven articles fully met our pre-determined criteria and were included in the meta-analysis. Results of the meta-analysis revealed that FSI level is significantly lower in Japanese patients than in Korean and Chinese patients. Conclusions Results from our review of Ethnic Differences in dietary habit in the inter-East Asian population suggested that Difference in dietary component was one of the most influential factors for the Ethnic Difference.
Minoru Takada - One of the best experts on this subject based on the ideXlab platform.
-
Ethnic Difference in hematological toxicity in patients with non small cell lung cancer treated with chemotherapy a pooled analysis on asian versus non asian in phase ii and iii clinical trials
Journal of Thoracic Oncology, 2011Co-Authors: Yoshikazu Hasegawa, Tomoya Kawaguchi, Akihito Kubo, Masahiko Ando, Junji Shiraishi, Shunichi Isa, Taisuke Tsuji, Kazuyuki Tsujino, Kazuhiko Nakagawa, Minoru TakadaAbstract:Introduction There are a large number of global clinical trials ongoing for patients with non-small cell lung cancer (NSCLC). Ethnic Difference in toxicity has not been adequately studied. Methods We performed a systematic search in PubMed for randomized phase II and III trials of NSCLC from January 2000 to December 2009, examining Ethnic Difference in hematological toxicity due to cytotoxic chemotherapy. Ethnicity was classified into Asian and non-Asian. We chose three treatment regimens used for NSCLC globally: cisplatin plus gemcitabine (CG), cisplatin plus vinorelbine (CV), and carboplatin plus paclitaxel (CP). We applied sensitivity analysis to examine unreported Ethnic Differences in hematological toxicities by changing the percentage of Asian patients from 0 to 18% in trials reported from the United States and Europe. Results We identified 12 phase II trials and 38 phase III trials of NSCLC with a total of 11,271 patients. Among these, 14 trials had reported Ethnic origins. Grade 3/4 toxicities were more frequently observed in the Asian studies. On the basis of sensitivity analysis, odds ratio of grade 3/4 neutropenia was significantly higher in Asian patients than non-Asian, when treated with CG (OR = 1.55–3.45, p p p p p p p p = 0.097–0.323), or CP (OR = 1.21–1.39, p = 0.114–0.152). Conclusions Severe hematological toxicity was frequently observed in Asian patients compared with non-Asian (mostly whites) in the treatment of chemotherapy for NSCLC.
-
Ethnic Difference in toxicity in non small cell lung cancer patients treated with chemotherapy a systematic review on phase ii and iii clinical trials
Journal of Clinical Oncology, 2010Co-Authors: Yoshikazu Hasegawa, Tomoya Kawaguchi, Akihito Kubo, Masahiko Ando, Junji Shiraishi, Shunichi Isa, Taisuke Tsuji, Kazuyuki Tsujino, Kazuhiko Nakagawa, Minoru TakadaAbstract:7638 Background: There are a large number of global clinical trials ongoing for patients with non-small cell lung cancer (NSCLC). Ethnic Difference in toxicity has not been fully studied. Methods: We performed a systematic search of PubMed for phase II (PII) and phase III (PIII) trials of NSCLC from January 2000 to December 2009 to examine Ethnic Difference in hematological toxicity due to cytotoxic chemotherapy. Ethnicity was classified into Asian and non-Asian (mostly Caucasian). We chose the treatment regimens that were commonly used globally including carboplatin (CBDCA) plus paclitaxel (PTX), cisplatin (CDDP) plus gemcitabine (GEM), and CDDP plus vinorelbine (VNR) for NSCLC. Because Ethnicity origins were not fully reported in the entire trials, we applied sensitivity analysis by changing the percentage of Asian patients from 5 to 15% in the trials reported from the United States and Europe. In these analysis, the percentage of toxicity in the Asian patients was settled as the mildest toxicity in the...
Hye Ryun Kim - One of the best experts on this subject based on the ideXlab platform.
-
pharmacogenetic determinants associated with sunitinib induced toxicity and Ethnic Difference in korean metastatic renal cell carcinoma patients
Cancer Chemotherapy and Pharmacology, 2013Co-Authors: Hye Ryun Kim, Hyung Soon Park, Woo Sun Kwon, Ji Hyun Lee, Yusuke Tanigawara, Sun Min Lim, Hyo Song Kim, S J Shin, Jung Bae Ahn, Sun Young RhaAbstract:Purpose The aim of this study was to investigate the pharmacogenetic determinants of sunitinib-related toxicity and Ethnic Difference in metastatic renal cell carcinoma (mRCC) among Korean patients.
-
abstract 2693 pharmacogenetic determinants associated with sunitinib induced toxicity and Ethnic Difference in korean patients with metastatic renal cell carcinoma
Cancer Research, 2012Co-Authors: Hye Ryun KimAbstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Purpose: The aim of this study was to investigate the pharmacogenetic determinants of sunitinib-related toxicity and Ethnic Difference in metastatic renal cell carcinoma (mRCC) among Korean patients. Experimental Design: A pharmacogenetic study was performed in 65 patients with mRCC treated with sunitinib (50mg orally once daily for 4 weeks-on/2 weeks-off). Detailed data regarding the toxicity of sunitinib, including thrombocytopenia, neutropenia, anemia, and hand-foot syndrome (HFS) were prospectively collected in a clinical trial program (n=38) or general oncology practice (n=27) using sunitinib. A total of 12 genetic polymorphisms in 7 candidate genes (CYP1A1, ABCG2, ABCB1, PDGFRα, VEGFR2, RET, and FLT3) were analyzed for an association with treatment-related toxicity using Pearson-χ2 test. Results: Common grade 3 or 4 treatment-related toxicities were thrombocytopenia (36.9%), neutropenia (18.4%), anemia (7.7%), and HFS (12.3%). Patients carrying an ABCG2 421 A/A genotype developed significantly more grade 3 or 4 thrombocytopenia, neutropenia, and HFS: odds ratio [OR] 10.15; P=0.03, thrombocytopenia, OR 17.33; P=0.003, neutropenia, OR 33.60; and P=0.005, HFS. Conclusion: c.421C>A genetic polymorphism in the ABCG2 gene may be most associated with the risk of sunitinib-related toxicity in mRCC patients. Considering the high frequency of ABCG2 c.421C>A SNP in Asian individuals, this may lead to differential toxicities among Ethnic groups. ![Figure][1] Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2693. doi:1538-7445.AM2012-2693 [1]: pending:yes
Masakazu Takeuchi - One of the best experts on this subject based on the ideXlab platform.
-
Ethnic Difference in patients with type 2 diabetes mellitus in inter east asian populations a systematic review and meta analysis focusing on gene polymorphism
Journal of Diabetes, 2009Co-Authors: Masakazu Takeuchi, Kousuke Okamoto, Tatsuya Takagi, Hitoshi IshiiAbstract:Background: We previously reported that the fasting serum insulin level was significantly lower in Japanese patients than in Korean and Chinese patients, and showed evidence that a Difference in the dietary component would be one of the most influential factors for the Ethnic Difference. However, it is well known that type 2 diabetes mellitus (T2DM) results from the interaction between genetic predispositions and environmental risk factors. Therefore, we investigated Ethnic Differences by focusing on gene polymorphism, possibly related to T2DM in Japanese, Korean, and Chinese subjects. Methods: Data sources included MEDLINE and EMBASE between January 2001 and October 2008. We conducted a search for articles containing minor allele frequency (MAF) in the gene polymorphisms of peroxisome proliferator-activated receptor-γ (PPARG), inward-rectifying potassium channel Kir6.2 (KCNJ11), Calpain 10 (CAPN10), and transcription factor 7-like 2 (TCF7L2). The pooled odds ratio was calculated by using a fixed-effects model with the Mantel–Haenszel method after confirming statistical evidence of homogeneity across the Ethnicities using the Breslow–Day test. Results: The Breslow–Day test revealed that there were no statistically significant Differences between Ethnicities in pooled odds ratios for the gene polymorphisms in PPARG (P = 0.828), KCNJ11 (P = 0.194), CAPN10 (P = 0.090), and TCF7L2 (P = 0.376). Also, pooled odds ratios of each gene polymorphism in East Asians were 0.645 for PPARG (P = 0.000), 1.168 for KCNJ11 (P = 0.000), 0.967 for CAPN10 (P = 0.759), and 1.386 for TCF7L2 (P = 0.000). Conclusion: The results of this study and our previous studies suggest that behavioral and environmental risk factors have a more significant impact on Ethnic Difference in East Asian patients with T2DM compared with genetic predispositions.
-
Ethnic Difference in inter east asian subjects with normal glucose tolerance and impaired glucose regulation a systematic review and meta analysis focusing on fasting serum insulin
Diabetes Research and Clinical Practice, 2008Co-Authors: Masakazu Takeuchi, Kousuke Okamoto, Tatsuya Takagi, Hitoshi IshiiAbstract:Abstract Aims To investigate Ethnic Difference by focusing on fasting serum insulin (FSI) in inter-East Asian subjects with normal glucose tolerance (NGT) and impaired glucose regulation (IGR). Methods Data sources included MEDLINE and EMBASE between 2001 and 2007. We conducted a search for articles containing mean or geometric mean values of FSI in East Asian subjects with NGT, IGR, or type 2 diabetes (T2DM). The Monte Carlo method was used for simulation of the mean and standard deviation of individual measures in each Ethnic group; calculation of the median ratio and 95% confidence interval of individual measures between Ethnic groups. Results Twenty-two articles fully met our pre-determined criteria and were included in the meta-analysis. Results of the meta-analysis revealed that FSI level is significantly lower in Japanese subjects with NGT, IGR, or T2DM than in Korean and Chinese subjects. Conclusions Ethnic Difference in FSI level between East Asians was observed in not only T2DM patients but also subjects with NGT or IGR. The lower FSI level in Japanese subjects was accompanied by lower triglyceride level. These results suggest that Ethnic Difference in dietary habit was one of the most influential factors for the Ethnic Difference in FSI.
-
Ethnic Difference in patients with type 2 diabetes mellitus in inter east asian populations a systematic review and meta analysis focusing on fasting serum insulin
Diabetes Research and Clinical Practice, 2008Co-Authors: Masakazu Takeuchi, Kousuke Okamoto, Tatsuya Takagi, Hitoshi IshiiAbstract:Abstract Aims To investigate Ethnic Difference by focusing on fasting serum insulin (FSI) in inter-East Asian patients with type 2 diabetes. Methods Data sources included MEDLINE and EMBASE between 2001 and 2006. We conducted a search for articles containing mean or geometric mean values of FSI in East Asian patients with type 2 diabetes. The Monte Carlo method was used for simulation of the mean and standard deviation of individual measures in each Ethnic group; calculation of the median ratio and 95% confidence interval of individual measures between Ethnic groups. Results The initial search identified a total of 996 journal articles. After reviewing the titles and abstracts of these articles, 201 studies were selected for further screening and the complete papers on these studies were then reviewed in detail. Of these, seven articles fully met our pre-determined criteria and were included in the meta-analysis. Results of the meta-analysis revealed that FSI level is significantly lower in Japanese patients than in Korean and Chinese patients. Conclusions Results from our review of Ethnic Differences in dietary habit in the inter-East Asian population suggested that Difference in dietary component was one of the most influential factors for the Ethnic Difference.
Yoshikazu Hasegawa - One of the best experts on this subject based on the ideXlab platform.
-
Ethnic Difference in hematological toxicity in patients with non small cell lung cancer treated with chemotherapy a pooled analysis on asian versus non asian in phase ii and iii clinical trials
Journal of Thoracic Oncology, 2011Co-Authors: Yoshikazu Hasegawa, Tomoya Kawaguchi, Akihito Kubo, Masahiko Ando, Junji Shiraishi, Shunichi Isa, Taisuke Tsuji, Kazuyuki Tsujino, Kazuhiko Nakagawa, Minoru TakadaAbstract:Introduction There are a large number of global clinical trials ongoing for patients with non-small cell lung cancer (NSCLC). Ethnic Difference in toxicity has not been adequately studied. Methods We performed a systematic search in PubMed for randomized phase II and III trials of NSCLC from January 2000 to December 2009, examining Ethnic Difference in hematological toxicity due to cytotoxic chemotherapy. Ethnicity was classified into Asian and non-Asian. We chose three treatment regimens used for NSCLC globally: cisplatin plus gemcitabine (CG), cisplatin plus vinorelbine (CV), and carboplatin plus paclitaxel (CP). We applied sensitivity analysis to examine unreported Ethnic Differences in hematological toxicities by changing the percentage of Asian patients from 0 to 18% in trials reported from the United States and Europe. Results We identified 12 phase II trials and 38 phase III trials of NSCLC with a total of 11,271 patients. Among these, 14 trials had reported Ethnic origins. Grade 3/4 toxicities were more frequently observed in the Asian studies. On the basis of sensitivity analysis, odds ratio of grade 3/4 neutropenia was significantly higher in Asian patients than non-Asian, when treated with CG (OR = 1.55–3.45, p p p p p p p p = 0.097–0.323), or CP (OR = 1.21–1.39, p = 0.114–0.152). Conclusions Severe hematological toxicity was frequently observed in Asian patients compared with non-Asian (mostly whites) in the treatment of chemotherapy for NSCLC.
-
Ethnic Difference in toxicity in non small cell lung cancer patients treated with chemotherapy a systematic review on phase ii and iii clinical trials
Journal of Clinical Oncology, 2010Co-Authors: Yoshikazu Hasegawa, Tomoya Kawaguchi, Akihito Kubo, Masahiko Ando, Junji Shiraishi, Shunichi Isa, Taisuke Tsuji, Kazuyuki Tsujino, Kazuhiko Nakagawa, Minoru TakadaAbstract:7638 Background: There are a large number of global clinical trials ongoing for patients with non-small cell lung cancer (NSCLC). Ethnic Difference in toxicity has not been fully studied. Methods: We performed a systematic search of PubMed for phase II (PII) and phase III (PIII) trials of NSCLC from January 2000 to December 2009 to examine Ethnic Difference in hematological toxicity due to cytotoxic chemotherapy. Ethnicity was classified into Asian and non-Asian (mostly Caucasian). We chose the treatment regimens that were commonly used globally including carboplatin (CBDCA) plus paclitaxel (PTX), cisplatin (CDDP) plus gemcitabine (GEM), and CDDP plus vinorelbine (VNR) for NSCLC. Because Ethnicity origins were not fully reported in the entire trials, we applied sensitivity analysis by changing the percentage of Asian patients from 5 to 15% in the trials reported from the United States and Europe. In these analysis, the percentage of toxicity in the Asian patients was settled as the mildest toxicity in the...